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Abstract
Background: Chronic immunosuppression is a known cause of Clostridioides difficile,
which presents with colon infection. It is associated with increased mortality and morbidity. Our aim is to determine the inpatient outcomes of liver transplant patients with
Clostridioides difficile infection (CDI) and trends in the last few years.
Methods: We utilized the national re-admission data (2010–2017) to study the outcomes of CDI in liver transplant patients. Association of C. difficile with re-admission
was computed in a multivariable model adjusted for age, sex, gastrointestinal bleeding,
hypertension, diabetes, hyperlipidemia, congestive heart failure, cerebrovascular disease, obesity, cancer, insurance, chronic kidney disease, chronic obstructive pulmonary
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disease, dementia, peripheral vascular disease, smoking, hospital location, and teaching
status.
Results: During 2010–2017, there were 310 222 liver transplant patients hospitalized.
Out of these, 9826 had CDI. CDI infection in liver transplant patients was associated
with higher 30-day re-admission (14.3% vs. 11.21%, hazard ratio [HR]: 1.14, 95% confidence interval [CI]: 1.01–1.28, p = .02) and in-hospital mortality (odds ratio [OR]: 1.36,
95% CI: 1.14–1.61, p < .001). The most common causes of re-admission in the CDI
group were recurrent CDI (41.1%), liver transplant complications (16.5%), and sepsis
(11.6%). The median cost for liver transplant patients with C. difficile was significantly
higher, $53 064 (IQR $24 970–$134 830) compared to patients that did not have C. difficile, $35 703 ($18 793–$73 871) (p < .001). The median length of stay was also longer
for patients with CDI, 6 days (4–14) vs. 4 days (2–7) (p < .001).
Conclusion: CDI in post-liver transplant patients was associated with higher mortality,
re-admission, health care cost, and longer length of stay. The most common cause of
re-admission was recurrent CDI, which raises the question of the efficacy of standard
first-line therapy.
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INTRODUCTION

provides de-identified information about the patients’ demographics
and hospital-based information. In addition, it provides information

Clostridioides (formerly Clostridium) difficile is a gram-positive, spore-

about the re-admission status. As a publicly available database was

forming bacteria that is one of the most common causes of nosocomial

used, the study was considered exempt from obtaining permission from

infection. It infects the colon and typically presents with diarrhea.1,2

the institutional review board.

The incidences of C. difficile infection (CDI) have increased in the last

We used the International Classification of Diseases, Ninth Edition

two decades and is reported as 147 cases per 10 000 people in the

(ICD-9) and ICD-10 diagnostic codes to identify patients with liver

United States.2,3 The traditional risk factors for CDI are antibiotics use,

transplant (ICD-9: 996.82, V42.7 and ICD-10: Z944, T86.40, T8641,

advanced age, health care exposure, chemotherapy, and immunocom-

T86.42, T86.4, T86.49, T86.42) and CDI (ICD-9: 008.45 and ICD-10:

promised state.1,4 Other risk factors include hypoalbuminemia, long

A04.72, A04.7, A04.71). All adult patients ≥18 years were included in

hospital stay, gastric acid suppression, obesity, tube feeding, and gas-

the study. Patients were excluded if they were discharged during the

trointestinal surgeries.2,5–7

month of December to ensure at least a 30-day follow-up. Based on this

The immune system is compromised by medications in solid organ
transplant (SOT) patients and potentially contributes to a higher risk

exclusion, we identified 9826 liver transplant patients with CDI with a
national estimate of 0.9%.

of CDI. Studies have suggested increased incidences of CDI post liver
transplant, which can be explained due to change in gastrointesti-

2.2

Patient and hospital characteristics

nal anatomy, prolonged hospital stay, frequent use of antibiotics, and
immunosuppressant use.8,9 The published data suggest that the incidence of CDI in SOT patients is 7.4%–11.8%.10,11 The studies had
reported up to 9% CDI cases in liver transplant recipients, and one
single-center study had shown the incidence of 18.9%.10,12,13 The CDI
is seen in the immediate post-transplant period. The peak time of onset
of infection is ranged from 6 to 31.5 days. The late-onset CDI is either
due to repeated antibiotic exposure or an increased dose of immunosuppression in the setting of rejection.12,14 The reported complications of the CDI in SOT population are fulminant colitis, renal failure,
colectomy, graft loss, and mortality.8,15–17 Surprisingly, a few studies

Baseline patient demographic characteristics (age, sex, race, hospital, and insurance payer) were extracted. The AHRQ Elixhauser
and Charlson’s comorbidity index was calculated to report the
comorbidities.23,24 Diagnostic codes were used to identify the history
of renal transplant, human immunodeficiency virus (HIV), pneumonia, complications of liver transplant hypertension, diabetes mellitus,
hyperlipidemia, obesity, chronic obstructive pulmonary disease, acute
kidney injury, chronic kidney disease, prior myocardial infarction, and
causes of liver diseases (Table S1). The discharge disposition and length
of stay were also reported.

had shown no major difference in mortality between CDI patients with
and without SOT.18–21 Although the comparative study by Gellad and
colleagues20 had shown that corticosteroid use was associated with

2.3

Outcomes

CDI irrespective of transplantation.
The prior studies on the CDI with liver transplants have variations
in study methodology, making it difficult to draw firm conclusions. A
better understanding is required for clinicians to improve management
and outcomes. Our aim is to determine the burden of CDI in the liver
transplant population using large national data. We also seek to estimate the in-hospital outcomes, including mortality, resource utiliza-

The primary outcome was 30-day all-cause re-admission and predictors of re-admission. In addition, predictors of mortality were also studied. We also evaluated the trends of 30-day re-admission and mortality.
In-hospital complications such as intubation, ICU admission, and use of
pressors were captured. We reported length of stay on re-admission
and index hospitalization.

tion, and hospital re-admission.

2.4
2

METHODS

Statistical analysis

Baseline characteristics were expressed as weighted values based
on discharge weights provided in the database. Continuous variables

2.1

Study population and design

with normal distribution were expressed as weighted mean ± standard deviations and with skewed distribution as weighted median

This retrospective study utilized national re-admission data (NRD),

with interquartile range (IQR). Categorical variables were expressed

which is a national representative cohort of hospitalized admissions

as weighted whole numbers with percentages. These were compared

that were admitted from January 1, 2010 to December 31, 2017. The

with the Pearson chi-square test and analysis of variance where appro-

NRD is a subgroup of the Healthcare Cost and Utilization Project

priate for patients with and without CDI. We computed the haz-

(HCUP). It is the nation’s largest inpatient database of encounter-level

ard ratio (HR) with 95% confidence intervals (CI) for the associa-

hospital care and all-payer data, which is sponsored by the Agency for

tion of 30-day re-admission in multivariable Cox regression models

Healthcare Research and Quality (AHRQ).22 It provides approximately

adjusted for age, sex, hypertension, diabetes mellitus, hyperlipidemia,

20% of the stratified sample of all hospitals in the United States, which

obesity, chronic obstructive pulmonary disease, acute kidney injury,

represents more than 95% of the national population. The database

chronic kidney disease, primary causes of liver disease, history of renal
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TA B L E 1

Baseline characteristics
Clostridioides difficile infection

Variables

Total cases
N = (310 151)

Present
(n = 9826)
50.6 ± 21.5

52.0 ± 20.2

.02

125 306 (40.4%)

4634 (47.2%)

120 672 (40.2%)

<.001

Age
Female

Absent
(n = 300 325)

p-Value

Hypertension

113 890 (36.7%)

3190 (32.5%)

110 700 (36.9%)

<.001

Hyperlipidemia

45 808 (14.8%)

1265 (12.9%)

44 543 (14.8%)

.003

Diabetes mellitus

130 454 (42.1%)

4118 (41.9%)

126 337 (42.1%)

.87

Smoker

68 067 (21.9%)

1833 (18.7%)

66 233 (22.1%)

<.001

Obesity

26 532 (8.55%)

713 (7.25%)

25 819 (8.6%)

.02

Chronic obstructive pulmonary disease

68 423 (22.1%)

2310 (23.5%)

66 113 (22.0%)

.10

Congestive heart failure

50 353 (16.2%)

1864 (19%)

48 489 (16.1%)

<.001

Acute kidney injury

86 074 (27.8%)

4063 (41.4%)

82 011 (27.3%)

<.001

Chronic kidney disease

154 091 (49.7%)

5505 (56%)

148 586 (49.5%)

<.001

Prior myocardial infarction

22 436 (7.23%)

703 (7.15%)

21 733 (7.24%)

.86

Cancer

39 648 (12.8%)

1416 (14.4%)

38 232 (12.7%)

.02

History of renal transplant

28 324 (9.13%)

951 (9.68%)

27 372 (9.11%)

.312

Complications of liver transplant

75 802 (24.4%)

2517 (25.6%)

73 285 (24.4%)

.22

Pneumonia

29 020 (9.36%)

1161 (11.8%)

27 858 (9.28%)

<.001

HIV

1171 (0.38%)

23 (0.24%)

1148 (0.38%)

.11

Any GI bleed

23 914 (7.71%)

1056 (10.7%)

22 857 (7.61%)

<.001

Teaching hospital

255 285 (82.3%)

8666 (88.2%)

246 620 (82.1%)

<.001

Urban hospital

266 520 (85.9%)

8897 (90.6%)

257 622 (85.8%)

<.001

ICU admission

17 916 (5.8%)

1072 (10.9%)

16 844 (5.6%)

<.001

Insurance

.10

Medicare

151 983 (49.1%)

4655 (47.5%)

147 328 (49.2%)

Medicaid

50 739 (16.4%)

1608 (16.4%)

49 130 (16.4%)

Private

95 880 (31.0%)

3247 (31.1%)

92 632 (30.9%)

Self-pay

3034 (0.98%)

59 (0.61%)

2975 (0.99%)

transplant, HIV, complications of the liver transplant, pneumonia,

with a diagnosis of CDI. The baseline characteristics of liver trans-

urban versus rural hospital location, teaching hospital status, insurance

plant patient admitted to hospital are given in Table 1. The patients

status, AHRQ mortality risk, all patient-defined DRG mortality risk,

with CDI were younger (50.6 ± 21.5 vs. 52.0 ± 20.2, p = .02), and had

and all patient refined severity of illness. For secondary outcomes such

higher percentage of female population (47.2% vs. 40.2%, p < .001).

as mortality, hospital charges, length of stay, we computed odds ratio

The prevalence of acute kidney injury (41.4% vs. 27.3%, p < .001),

(OR) with 95% CI in multivariable-adjusted logistic regression mod-

chronic kidney disease (56% vs. 49.5%, p < .001), malignancies (14.4%

els adjusted for the variables given above after removing the outcome

vs. 12.7%, p = .02), GI bleed (10.7% vs. 7.61%, p < .001), and pneumonia

variable. Weighted analyses were used for all statistical calculations.

(11.8% vs. 9.28%, p < .001) were higher in liver transplant patients with

Statistical analysis was performed using STATA version 14.2 (College

CDI, whereas hypertension (32.5% vs. 36.9%, p < .001), hyperlipidemia

Station, TX). All p-values were two-sided, with a significance threshold

(12.9% vs. 14.8%, p = .003), smoking (18.7% vs. 22.1%, p < .001), and

of p < .05.

obesity (7.25% vs. 8.6%, p = .02) prevalence was lower in CDI population. A higher number of C. difficile patients were admitted in teaching,
urban hospitals, and required ICU admissions (Table 1).

3

RESULTS

Hepatitis C was the most common etiology in the liver transplant
cohort, followed by nonalcoholic fatty liver disease. The patients with

Among 310 151 hospitalizations with a history of liver transplant in

C. difficile had a higher prevalence of history of alcohol liver disease

the NRD database during 2010–2017, there were 9826 (3.2%) patients

(8.7% vs. 7.7%, p = .002) and primary biliary cholangitis (1.17% vs.
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TA B L E 2 Primary outcomes and association with Clostridioides
difficile infection

and primary sclerosing cholangitis (HR: 1.15, 95% CI: 1.02–1.3) were
associated with a higher likelihood of 30-day re-admission. The other

Outcomes

Hazard ratio

p-Value

independent factors associated with increased 30-day re-admission

Inpatient mortality
(odds ratio)

1.36 (1.14–1.61)

<.001

were liver transplant-related complications and history of gastroin-

Length of stay
(beta coefficient)

5.87 (5.09–6.65)

<.001

Length of stay in survivors
(beta coefficient)

5.68 (4.90–6.44)

<.001

Hospital charges
(beta coefficient)

58 841 (47 827–69 856) <.001

Hospital charges in survivors
(beta coefficient)

52 732 (42 757–62 706) <.001

30-Day re-admission

1.14 (1.02–1.29)

testinal bleed, acute kidney injury, chronic kidney disease, diabetes
mellitus, chronic obstructive pulmonary disease, and coronary artery
disease (Figure 1 and Table S4A).
The most common cause of re-admission in the study group was
CDI (578, 41.1%), followed by complications of transplant (233, 16.5%),
sepsis (160, 11.4%), acute kidney injury (51, 3.6%), and pneumonia (48,
3.4%), whereas the complication of the liver transplant was the most
common cause of re-admission in the non-CDI liver transplant population (Table 4).
.02

3.2

Secondary outcomes

0.87%, p = .04), whereas the patients without C. difficile had higher
prevalence of history of hepatitis C (15.1% vs. 13%, p = .001) and hep-

After the liver transplant, the mortality rate was higher (OR: 1.36, 95%

atitis B (1.91% vs. 1.45%, p = .02) (Table S2). The median length of stay

CI: 1.14–1.61, p < .001) in the C. difficile population. The liver trans-

in liver transplant patients with CDI was higher, 6 days (IQR 4–14), as

plant patients with a history of alcohol liver disease (OR: 1.26, 95%

compared to those without CDI, 4 days (IQR 2–7) p < .001 (Table 2).

CI: 1.05–1.52) and hepatocellular cancer (OR: 1.54, 95% CI: 1.27–1.87)
also had higher mortality. The other independent predictors associated
with higher in-hospital mortality were older age, gastrointestinal bleed,

3.1

Predictors of 30-day re-admission

acute kidney injury, history of renal transplant, post-liver transplant
complications, pneumonia, and coronary artery disease (Figure 2 and

The liver transplant patients with C. difficile had a higher 30-day re-

Table S4B).

admission rate (14.3% vs. 11.21%, HR: 1.14, 95% CI: 1.01–1.28) as

The patients with C. difficile had more complicated hospital stay

compared to non-C. difficile patients. Patients with alcohol liver disease

requiring intensive care unit (ICU) admission (OR: 1.76, 95% CI:

(HR: 1.19, 95% CI: 1.04–1.36), hepatocellular cancer (HR: 1.26, 95% CI:

1.55–2.00), intubations (OR: 1.85, 95% CI: 1.60–2.13, p < .001),

1.07–1.48), autoimmune liver disease (HR: 1.20, 95% CI: 1.03–1.41),

esophagogastroduodenoscopy (EGD) (OR: 1.39, 95% CI: 1.17–1.67,

FIGURE 1

Forest plot showing the predictors of the 30-days re-admission in hospitalized liver transplant patients
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FIGURE 2

Forest plot showing predictors of inpatient mortality in hospitalized liver transplant patients

TA B L E 3 Association of Clostridioides difficile infection with
secondary outcomes
Outcomes

Odds ratio (95% CI)

p-Value

ICU admission

1.76 (1.55–2.00)

<.001

Intubation

1.85 (1.60–2.13)

<.001

Pressors use

1.22 (0.85–1.76)

.27

Esophagogastroendoscopy

1.39 (1.17–1.67)

<.001

Colonoscopy

1.95 (1.64–2.31)

<.001

TA B L E 4 Top five major causes of re-admissions in Clostridioides
difficile infection patients
Etiologies

N

Clostridioides difficile

578

Complications of liver transplant

233

Sepsis

160

Acute kidney injury

51

Pneumonia

48

F I G U R E 3 Trends of Clostridioides difficile infection in liver
transplant patients (2010–2017)

$35 703 (IQR: $18 793–$73 871) as compared to non-CDI liver transplant patients; p < .001. This difference stays statistically significant in
survivors (Table 2).

p < .001), and colonoscopies (OR: 1.95, 95% CI: 1.64–2.31, p < .001)

3.4

(Table 3).

3.3

Hospital cost

Trends of CDI in liver transplant patients

The trends of CDI prevalence had increased modestly from 2010 to
2017 (2.4% vs. 3.1%), whereas in-hospital mortality (18.5% vs. 14%)

The data suggested that the liver transplant patients with CDI had a

and 30-day re-admission (6.4% vs. 3.6%) had slightly improved in the

higher inflation adjusted cost of $53 064 (IQR: $24 970–$134 830) vs.

last decade (Figure 3 and Table S3).
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DISCUSSION

of subsequent recurrent infection. If the logistic allows, bezlotoxumab
can benefit patients with primary CDI with a high risk of recurrence

This study of the liver transplant cohort demonstrated CDI preva-

(advanced age, severe infection, and immunocompromised state).27

lence of 32 per 1000 patients. The patients hospitalized with C. difficile

There is no transplant-specific guideline. There is a fear of vancomycin-

had a more severe illness, and the CDI was independently associated

resistant Enterococcus (VRE) with vancomycin use in the immunocom-

with 36% higher mortality and 14% higher 30-day re-admission. The

promised population.28 Our study utilized the data prior to the recent

patients with alcoholic liver disease and hepatocellular cancer were

IDSA guidelines. The fecal microbiota transplant in SOT has promis-

associated with higher 30-day re-admission rates and mortality. The

ing outcomes in the published studies,29 but there is weak evidence as

length of stay, ICU admissions, and hence total costs were also higher in

prospective data are limited.30

CDI. The trend of the CDI rate in liver transplant patients has increased

There are several implications of our study. First, this study shows

in the last decade. Interestingly, CDI was the most common cause of re-

that having a diagnosis of CDI in the liver transplant population is

admission as compared to non-CDI patients, who were mostly readmit-

not benign. It leads to increased mortality, hospital re-admission, and

ted because of liver transplant-related complications.

resources utilization, including more procedures, length of stay, hence

Previously, a single-center study analyzed 10 years of data and

higher cost. Second, we found that the most common cause of re-

demonstrated a high incidence of CDI in liver transplant patients, and

admission was the CDI. This suggests more intense treatment in liver

a majority of them were observed in the first year of transplant. The

transplant patients and consideration of bezlotoxumab as adjunctive

predictors of developing CDI were White race, length of stay, and pre-

treatment in primary infection cases.

transplant model for end-stage liver disease (MELD) score. The recur16.9%.13

There are several limitations due to the retrospective nature of the

Similarly, a small study had identified length

study. As NRD are often created for financial and administrative pur-

of stay, pre-transplant antibiotic use, prior history of CDI, CKD, and

poses, these lack certain pertinent clinical information such as radio-

exposure to proton pump inhibitors as possible risk factors for post-

logical information, laboratory data, sequence of events, medications

rence rate was

CDI.21

Another retrospective study recaptured simi-

use, and biomarkers. As a result, we did not comment on the stool col-

lar results, and live donor liver transplant patients had a higher inci-

onization and antimicrobial’s affectivity. Additionally, it does not fully

dence of CDI, although the number of these observations was small.14

reflect all national hospitalizations, as NRD account for 20% of all US

Usually, the MELD score is lower in live donor recipients; it is difficult

hospitalizations and the national estimations are generated using dis-

to establish a pre-transplant MELD score as a true risk factor in these

charge weight estimates, it may underestimate the true prevalence

patients.

of CDI amongst patients with liver transplantation. Finally, only in-

liver transplant

A national database study had shown a three-fold increase in the

hospital outcomes are measured, and the exact cause of death is not

prevalence of CDI in the hospitalized liver transplant patients, which

available. Despite these limitations, the NRD still provide an important

was also associated with increased mortality as compared to the non-

understanding of the effects of hospitalized CDI in the liver transplant

CDI liver transplant

patients.17

One national inpatient sample (NIS)

population with large statistical power.

study utilized 2016 data and showed an increased risk of shock, organ

The CDI in liver transplant recipients continues to increase. It is

failure, and ICU admission in CDI with a liver transplant, but the mor-

associated with higher mortality, prolonged length of stay, higher re-

tality was not different from non-transplant patients.19 Another study

admission, and resource utilization. The judicial use of antibiotics,

utilized NIS and showed the same 2.7% prevalence of CDI in SOT

immunosuppression, acid suppressive medications, and shorter hospi-

patients, and these patients had adverse

outcomes.25

Our study uti-

lized the same administrative data and reproduced similar results. The

tal stay can reduce the incidence of CDI. More intense doses and duration of the medical treatment can improve the re-admission rates.

prevalence of CDI has increased in hospitalized patients to 3.2% as per
our observation. We also looked at the re-admission rates and deter-
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